Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Belén Garijo López

CEOBelén Garijo López

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

105.36B

Market cap105.36B

Price-Earnings ratio

18.59

Price-Earnings ratio18.59

Dividend yield

3.95%

Dividend yield3.95%

Average volume

2.36M

Average volume2.36M

High today

$44.19

High today$44.19

Low today

$43.31

Low today$43.31

Open price

$43.41

Open price$43.41

Volume

4.03M

Volume4.03M

52 Week high

$52.68

52 Week high$52.68

52 Week low

$42.28

52 Week low$42.28

SNY News

TipRanks 7h

Sanofi Ends Phase 2 Amlitelimab Alopecia Trial, Nudging Investor Expectations

Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi has terminated a Phase 2 trial that tested amlitelimab as a stand‑alone treatment fo...

Investor's Business Daily 9h

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

Technology Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit Licensing Sanofi (SNY) scrapped a final-phase study Wednesday of a...

TipRanks 10h

Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright

After Sanofi (SNY) announced that it is stopping the pivotal MOBILIZE study evaluating riliprubart in chronic inflammatory demyelinating polyneuropathy patients...

Analyst ratings

57%

of 7 ratings

Buy

42.9%

Hold

57.1%

Sell

More SNY News

Nasdaq 11h

Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results

Sanofi SNY announced that it is discontinuing the phase III MOBILIZE study, which is evaluating its investigational drug, riliprubart, in patients with chronic...

TipRanks 11h

Morning Movers: Dianthus plummets after peer Sanofi halts trial

Stocks are under pressure this morning as investors confront escalating U.S.-Iran tensions and a highly anticipated inflation report. Futures are pointing lower...

TipRanks 12h

Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus

Stifel notes that Sanofi (SNY) announced this morning that they are discontinuing the MOBILIZE Phase 3 study of riliprubart in CIDP patients refractory to IVIg...

TipRanks 3d

Sanofi’s Venglustat Wins FDA Priority Review for Type 3 Gaucher Disease

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 5d

OWKIN Deepens Sanofi Collaboration With Multi-Year AI-Driven Biopharma Partnership - TipRanks

...

TipRanks 5d

Sanofi and Kymera Advance SAR447971 Into First-in-Human Trial, Setting Up New Optionality in Inflammatory Skin Disease

Kymera Therapeutics, Inc. (KYMR), Sanofi SA (SNY) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRank...

TipRanks 5d

Novavax and Sanofi Advance Omicron JN.1 Booster With Completed Phase 3 Study

Novavax (NVAX) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.